Michael T. Andriole

Filings by Michael T. Andriole span 2 companies, the busiest being Chimerix Inc and Endocyte Inc. Over a trading history stretching from 20 February 2017 to 21 April 2025, the count stands at 26 filings.

The open-market side counts 4 purchases for €263k alongside 6 sales for €286k. Netting one side against the other leaves €23k of net selling. Unlike grants, an open-market purchase is paid for by the insider, at the market price. Besides market trades, the filings include 7 share grants and 2 option exercises. Since January 2025: no purchases and 2 sales on the market.

A typical purchase (the median) is worth €49k. On 4 out of 4 purchases, another insider of the same company was buying within the same 30 days. Purchases made close together by different insiders form what is called a cluster.

On 21 April 2025 came the latest disclosure, a transaction for €4.7M in Chimerix Inc. The most recent open-market purchase was published on 19 May 2023, 1,254 days ago. Typically, a trade is published a median of 1 day after it takes place. The legal deadline for a Form 4 is two business days after the transaction. Sales are harder to read than purchases, since they often meet personal needs such as tax or diversification. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.